CytomX Therapeutics (CTMX)
(Real Time Quote from BATS)
$2.38 USD
-0.01 (-0.42%)
Updated Aug 5, 2025 10:26 AM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTMX 2.38 -0.01(-0.42%)
Will CTMX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
Other News for CTMX
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
CytomX Therapeutics (CTMX) Receives 'Outperform' Rating from Oppenheimer | CTMX Stock News
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX ...